- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05850598
Effect of rTMS of the Cerebellum on Parkinson's Disease
Effect of Low-frequency rTMS of the Cerebellum on Parkinson's Disease
Study Overview
Status
Intervention / Treatment
Detailed Description
The main question it aims to answer is: how to improve Parkinson's disease by rTMS.
Participants will be treated with active low-frequency rTMS/sham rTMS over the cerebellum and receive: 1) resting state functional magnetic resonance imaging (fMRI), 2) blood sampling, and 3) Unified Parkinson Disease Rating Scale (UPDRS) before and after the treatment course.
Researchers will compare the data collected from fMRI scan, blood sample analysis, and UPDRS rating between the active rTMS group and sham controls before and after the treatment to see if there are meliorating effects of rTMS on Parkinson's disease.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Xiao-Yang Zhang, Ph.D.
- Phone Number: +8617712424530
- Email: xiaoyangzhang@nju.edu.cn
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Recruiting
- Nanjing Brain Hospital
-
Contact:
- Yang Pan, M.D.
- Phone Number: +8613952098253
- Email: neuro_panyang@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosed with Parkinson's disease according to the clinical diagnostic criteria for Parkinson's disease (2015 edition) by the Movement Disorder Society (MDS)
- Citizens of the People's Republic of China of either sex, aged between 40 and 80 years.
- Able to give informed consent and follow the research plan.
- Hoehn-Yahr (H-Y) stage ≤ 3
- Patients received a Parkinson's stable medication before treatment (assessed via self report), which continued during treatment.
Exclusion Criteria:
- History or diagnosis of severe psychiatric disorders, such as depression, anxiety disorders, schizophrenia spectrum disorders, and bipolar disorders.
- Subjects with a clinically defined neurological disorder (assessed via self report) including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, history of stroke, transient ischemic attack within two years, cerebral aneurysm, dementia, multiple sclerosis.
- Significant cognitive disorders (Mini-Mental State Exam (MMSE)<24 points) or unable to complete the questionnaire independently.
- Intracranial implants, such as cochlear implants, aneurysms clips, shunts, stimulators, electrodes, cardiac pacemakers and vagus nerve stimulation devices.
- Increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or currently taking medication that lowers the seizure threshold (assess via self report).
- Showed significant discomfort after receiving the rTMS treatment.
- Participated in other clinical trials.
- Inability to read or understand Chinese.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: sham stimulation targeting the cerebellum
Patients will be randomly allocated into this group, and they will receive sham stimulation.
|
The coil was held while disconnected from the stimulator, and rTMS noise was presented with computer loudspeakers with recorded sound from a real stimulation (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
|
Active Comparator: real rTMS targeting the cerebellum
Patients will be randomly allocated into this group, and they will receive real stimulation.
|
Low-frequency (1 Hz) rTMS at with a stimulation intensity of 95% of the motor threshold will be delivered over the bilateral cerebellum for patients with Parkinson's disease (20 minutes for each side of the lateral cerebellum everyday for 2 weeks).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of Unified Parkinson's Disease Rating Scale (UPDRS) (version 3.0) score by rTMS treatment
Time Frame: Baseline, 2 weeks, and 3 months after rTMS treatment
|
UPDRS score will be collected from each participants to measure the severity and progression of Parkinson's disease with scores ranging from 0 (minimum) to 199 (maximum).
The higher scores mean a worse outcome.
|
Baseline, 2 weeks, and 3 months after rTMS treatment
|
Changes of brain plasticity by rTMS treatment
Time Frame: Baseline, 2 weeks, and 3 months after rTMS treatment
|
Resting state fMRI will be scanned from each participants, and brain activity as well as fuctional connectivity will be analyzed.
|
Baseline, 2 weeks, and 3 months after rTMS treatment
|
Changes of circulating serum level of inflammatory cytokines (e.g., Interleukin-1beta (IL-1β), Interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α)) by rTMS treatment
Time Frame: Baseline, 2 weeks, and 3 months after rTMS treatment
|
Blood samples will be collected from each participants, and serum levels of IL-1β, IL-6, and TNF-α will be measured by enzyme-linked immunosorbent assay (ELISA).
|
Baseline, 2 weeks, and 3 months after rTMS treatment
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Yang Pan, M. D., Jiangsu Province Nanjing Brain Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PDTMS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on sham rTMS
-
Chang Gung Memorial HospitalRecruiting
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Chang Gung Memorial HospitalMinistry of Science and Technology, TaiwanRecruiting
-
Bayside HealthCompletedAutistic Disorder | Asperger's DisorderAustralia
-
Duke UniversityNational Institute on Aging (NIA)Completed
-
Dr. Alexander ThielCompletedAphasiaCanada, United States, Germany
-
Dr. Zahra Kazem-MoussaviCompleted
-
University of Maryland, BaltimoreRecruiting
-
Butler HospitalCompletedObsessive-Compulsive DisorderUnited States
-
VA Office of Research and DevelopmentCompleted